3.46
-0.11 (-3.08%)
| 前收盘价格 | 3.57 |
| 收盘价格 | 3.52 |
| 成交量 | 1,259,535 |
| 平均成交量 (3个月) | 2,008,542 |
| 市值 | 571,730,240 |
| 市盈率 (P/E TTM) | 4.49 |
| 价格/销量 (P/S) | 1.82 |
| 52周波幅 | |
| 利润日期 | 9 Nov 2026 |
| 营业毛利率 | -10.18% |
| 营业利益率 (TTM) | -25.64% |
| 稀释每股收益 (EPS TTM) | -0.190 |
| 季度收入增长率 (YOY) | -45.10% |
| 季度盈利增长率 (YOY) | -76.20% |
| 流动比率 (MRQ) | 3.34 |
| 营业现金流 (OCF TTM) | 78.52 M |
| 杠杆自由现金流 (LFCF TTM) | 83.30 M |
| 资产报酬率 (ROA TTM) | 12.03% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Ironwood Pharmaceuticals, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.7 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | 4.3 |
| 宏观环境 | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.33 |
|
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 2.68% |
| 机构持股比例 | 97.41% |
该时间范围内无数据。
该时间范围内无数据。
投资组合